Pinned post
Pulmonary Hypertension at Penn
@PennMedPH
Follow for updates from the Penn Pulmonary Hypertension Team, a devoted group committed to bettering the lives of our patients.
145 Following 890 Followers 306 Posts
Latest posts 5
Sotatercept for the treatment of PAH within the first year of diagnosis @NEJM @ATS_PC
nejm.org/doi/full/10.10…
nejm.org/doi/full/10.10…
www.nejm.org Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis | NEJM Sotatercept, an activin-signaling inhibitor, reduces morbidity and mortality among patients with long-standing pulmonary arterial hypertension. Its effects in patients with pulmonary arterial hyper... 🚨 Exciting news! 🚨
Our very own @DoctorBreanne will present her abstract at the Best of ATS 2025 @ATS_PC webinar! 🎉👏
📅 Tuesday, Aug 26
⏰ 3–4 PM EST
🔗 Register: site.thoracic.org/events/topic-b…
Our very own @DoctorBreanne will present her abstract at the Best of ATS 2025 @ATS_PC webinar! 🎉👏
📅 Tuesday, Aug 26
⏰ 3–4 PM EST
🔗 Register: site.thoracic.org/events/topic-b…
site.thoracic.org Best of ATS 2025 – Pulmonary Circulation… | American Thoracic Society The American Thoracic Society is the world's leading medical society dedicated to accelerating the advancement of global respiratory health through… Hot off the press - Ambient air pollution exposure and mortality in the @PHAssociation registry. @atscommunity @ATS_PC
atsjournals.org/doi/abs/10.151…
atsjournals.org/doi/abs/10.151…
In a small series of PAH patients treated with sotatercept, withdrawal of selexipag was found to be safe, while discontinuation of parenteral treprostinil was feasible only in a subset of patients
bit.ly/41UKcUi
bit.ly/41UKcUi
